Investment Analysts’ Recent Ratings Updates for Arcutis Biotherapeutics (ARQT)

Several analysts have recently updated their ratings and price targets for Arcutis Biotherapeutics (NASDAQ: ARQT):

• 11/7/2026 – Arcutis Biotherapeutics was downgraded by Wall Street Zen from “buy” to “hold”.
• 11/5/2026 – Arcutis Biotherapeutics was given a new $40.00 price target by Needham & Company LLC.
• 11/5/2026 – Arcutis Biotherapeutics had its price target raised by TD Cowen from $35.00 to $40.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Arcutis Biotherapeutics was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 10/19/2026 – Arcutis Biotherapeutics had its price target raised by Guggenheim from $38.00 to $44.00. They now have a “buy” rating on the stock.
• 10/15/2026 – Arcutis Biotherapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $48.00 price target on the stock.
• 10/14/2026 – Arcutis Biotherapeutics was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 10/10/2026 – Arcutis Biotherapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 10/8/2026 – Arcutis Biotherapeutics had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $39.00 price target on the stock.
• 9/24/2026 – Arcutis Biotherapeutics was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.

Arcutis Biotherapeutics Trading Up 2.7%

Shares of ARQT opened at $28.13 on Wednesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.92 and a quick ratio of 2.66. Arcutis Biotherapeutics, Inc. has a 1 year low of $19.30 and a 1 year high of $34.80. The company has a 50 day simple moving average of $27.28 and a two-hundred day simple moving average of $25.37. The firm has a market cap of $3.56 billion, a P/E ratio of 133.95 and a beta of 1.66.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its earnings results on Wednesday, November 4th. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.12). The company had revenue of $143.92 million during the quarter, compared to analysts’ expectations of $142.59 million. Arcutis Biotherapeutics had a return on equity of 14.18% and a net margin of 5.88%. On average, equities analysts expect that Arcutis Biotherapeutics, Inc. will post 0.28 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Todd Watanabe sold 4,377 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $31.86, for a total transaction of $139,451.22. Following the completion of the transaction, the insider directly owned 712,826 shares of the company’s stock, valued at approximately $22,710,636.36. This represents a 0.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Howard G. Welgus sold 4,730 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $26.18, for a total value of $123,831.40. Following the transaction, the director owned 36,475 shares of the company’s stock, valued at $954,915.50. This represents a 11.48% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 108,932 shares of company stock valued at $3,158,225. 9.40% of the stock is owned by corporate insiders.

Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin diseases. Founded in 2016, the company is headquartered in Westlake Village, California. Arcutis primarily serves the U.S. market and continues to develop medicines for dermatologic conditions. Its leadership is headed by President and Chief Executive Officer Frank Watanabe.